Multiple Myeloma News
Here are all the latest news articles written by The Beacon’s staff.
For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, Kyprolis, Pomalyst (Imnovid), Revlimid, thalidomide, Velcade, and Zometa.
For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708), marizomib (NPI-0052), MOR202, oprozomib, panobinostat, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).
For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathy, secondary cancer, smoldering multiple myeloma, and stem cell transplants.
Read the full story »
Results of a small preclinical study conducted at the Karmanos Cancer Center in Detroit indicate that the oral anesthetic dyclonine may enhance the anti-myeloma activity of Velcade.
Dyclonine is the active ingredient in the Sucrets brand of sore throat lozenges, which are sold over-the-counter in drugstores and other retailers in Canada and the United States. Sucrets lozenges are marketed by Insight Pharmaceuticals.
The Karmanos researchers conducted laboratory tests of dyclonine’s activity against the so-called “RPMI8226″ line of myeloma cells, which is commonly used in pre-clinical testing of potential myeloma therapies. …
Read the full story »
OncoPep, a biotech company developing a potential therapeutic vaccine for multiple myeloma, is the Myeloma Beacon’s newest pharmaceutical industry sponsor.
OncoPep was founded in 2010 to develop novel cancer immunotherapies that stimulate a patient’s own immune system to attack cancer cells. The company’s first investigational immunotherapy is PVX-410, a cancer vaccine based on research in the laboratory of Dr. Kenneth Anderson and Dr. Nikhil Munshi at the Dana-Farber Cancer Institute in Boston.
“OncoPep’s decision to support The Myeloma Beacon is yet another example of a forward-looking organization finding itself aligned …